It has been suggested that RT, in conjunction with MSLN-targeting CAR-T treatment, represents a viable strategy for enhancing tumor microenvironment modulation, CAR-T cell trafficking and anti-cancer effects in patients with unresectable PDAC [22]. This evidence concerns the gene MSLN and cancer.